Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Gene therapy for Fanconi anemia

Agnieszka Czechowicz • 25 Apr 2022
The 2022 Tandem Meetings
Anemias Rare Diseases

Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, explains the procedure of gene therapy for Fanconi Anemia. Currently, only patients with the FANCA subtype can be treated with gene therapy. Gene therapy is performed ex vivo using lentiviral vectors. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Agnieszka Czechowicz

Key challenges that remain in the treatment and management of Fanconi anemia
1:20
Key challenges that remain in the treatment and management of Fanconi anemia
Agnieszka Czechowicz • 7 Dec 2024
Robust immune reconstitution in Fanconi anemia mice following in-utero HSCT
1:47
Robust immune reconstitution in Fanconi anemia mice following in-utero HSCT
Agnieszka Czechowicz • 7 Dec 2024
Briquilimab-based conditioning for patients with Fanconi anemia receiving alloSCT
2:02
Briquilimab-based conditioning for patients with Fanconi anemia receiving alloSCT
Agnieszka Czechowicz • 7 Dec 2024
Restoring the hematolymphoid system in Fanconi anemia
1:29
Restoring the hematolymphoid system in Fanconi anemia
Agnieszka Czechowicz • 25 Apr 2022

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
1:48
Managing ruxolitinib-associated anemia in myelofibrosis: dose reduction and add-on therapies
Ciro Rinaldi • 10 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals